Chemotoxicity:
264 (43.5%) non-metastatic OGS, 53 (37.3%) metastatic OGS, 54 (51.9%)
non-metastatic ES and 16 (42.1%) metastatic ES cases had febrile
neutropenia, with 121 (19.9%) non-metastatic OGS, 48 (33.8%)
metastatic OGS, 24 (23.1%) non-metastatic ES and 14 (36.8%) metastatic
ES requiring dose modification of at least one drug, respectively.